Perrigo receives FDA approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)

Editorial Checklist Reviewed
Mar 24 2009NewsGuard 100/100 Score

Perrigo Company has announced that it has received final approval from the U.S. Food and Drug Administration to market Sulfacetamide Sodium Topical Suspension, 10% (Lotion).

The product has been determined to be therapeutically equivalent (AB) to Sanofi-Aventis' Klaron(R) (Sodium Sulfacetamide) Lotion, 10%, which is indicated for the topical treatment of acne. Klaron(R) Lotion had sales of approximately $15 million for the 12 months ended January 2009, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This approval is another example of our commitment to invest in and bring new products to market. It further demonstrates our strategy to deliver quality affordable healthcare both behind and over the counter."

Source:

http://www.perrigo.com/

Posted in: Pharmaceutical News

Tags: , ,

Comments (0)

Suggested Reading

Limiting fast-food outlets can reduce childhood overweight and obesity
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Ultra-processed food linked to weight gain and lower well-being in adolescents
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood
Six common flying with food allergies myths
Frequent ultra-processed food consumption raises mortality risks, especially in women
Online food shopping: Are you getting the information you need?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Living in food deserts during early childhood raises long-term obesity risk